Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Price Pass Below Two Hundred Day Moving Average – What’s Next?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT)’s stock price crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $30.61 and traded as low as $27.78. Lakefront Biotherapeutics American Depositary Shares shares last traded at $27.84, with a volume of 167,206 shares trading hands.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on LKFT. Wall Street Zen downgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Morgan Stanley started coverage on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Friday, July 10th. They set an “equal weight” rating and a $30.00 price target for the company. Weiss Ratings reissued a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Tuesday, May 26th. Finally, Zacks Research upgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a research report on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $34.33.

Lakefront Biotherapeutics American Depositary Shares Trading Down 1.0%

The firm has a fifty day simple moving average of $28.75 and a two-hundred day simple moving average of $30.61. The firm has a market cap of $1.83 billion, a PE ratio of -19.74 and a beta of 0.25.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.27) by $1.52. The business had revenue of $8.75 million for the quarter, compared to analysts’ expectations of $11.26 million. Equities analysts expect that Lakefront Biotherapeutics American Depositary Shares will post -10.83 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. State of Wyoming bought a new position in Lakefront Biotherapeutics American Depositary Shares in the 2nd quarter worth $28,000. Van ECK Associates Corp boosted its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 61.6% during the 4th quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 750 shares in the last quarter. Arax Advisory Partners boosted its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 319.2% during the 4th quarter. Arax Advisory Partners now owns 2,335 shares of the biotechnology company’s stock valued at $76,000 after purchasing an additional 1,778 shares in the last quarter. Quadrant Capital Group LLC purchased a new position in shares of Lakefront Biotherapeutics American Depositary Shares during the third quarter valued at about $134,000. Finally, Squarepoint Ops LLC purchased a new position in shares of Lakefront Biotherapeutics American Depositary Shares during the third quarter valued at about $211,000. 32.46% of the stock is owned by hedge funds and other institutional investors.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.